Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Gemcitabine, Bevacizumab and Erlotinib in Locally Advanced and Metastatic Pancreatic Cancer

NCT00366457 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT00366457
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00366457 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Gemcitabine, Bevacizumab and Erlotinib in Locally Advanced and Metastatic Pancreatic Cancer
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2006
Completion date
July 31, 2011
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the pancreas, pancreatic cancer